These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 26084616)

  • 21. Serum total gangliosides level: clinical prognostic implication.
    Nicolae I; Nicolae CD; Coman OA; Stefănescu M; Coman L; Ardeleanu C
    Rom J Morphol Embryol; 2011; 52(4):1277-81. PubMed ID: 22203934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.
    Saiag P; Aegerter P; Vitoux D; Lebbé C; Wolkenstein P; Dupin N; Descamps V; Aractingi S; Funck-Brentano E; Autier P; Dragomir M; Boniol M
    J Natl Cancer Inst; 2015 Dec; 107(12):djv264. PubMed ID: 26376687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients.
    Logozzi M; De Milito A; Lugini L; Borghi M; Calabrò L; Spada M; Perdicchio M; Marino ML; Federici C; Iessi E; Brambilla D; Venturi G; Lozupone F; Santinami M; Huber V; Maio M; Rivoltini L; Fais S
    PLoS One; 2009; 4(4):e5219. PubMed ID: 19381331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients.
    Weinlich G; Murr C; Richardsen L; Winkler C; Fuchs D
    Dermatology; 2007; 214(1):8-14. PubMed ID: 17191041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
    Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
    Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
    Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of caveolin family proteins in serum of patients with systemic lupus erythematosus.
    Li M; Zhang YJ; Liu DX; Liu Z; Fu M; Yang QR; Sun HS
    Lupus; 2021 Oct; 30(11):1819-1828. PubMed ID: 34569384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
    Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
    Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients.
    Panasiti V; Curzio M; Roberti V; Lieto P; Devirgiliis V; Gobbi S; Naspi A; Coppola R; Lopez T; di Meo N; Gatti A; Trevisan G; Londei P; Calvieri S
    Dermatology; 2013; 227(1):55-61. PubMed ID: 24008289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
    Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
    Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
    Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
    Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer.
    Tas F; Tilgen Yasasever C; Karabulut S; Tastekin D; Duranyildiz D
    Biomed Pharmacother; 2015 Mar; 70():19-23. PubMed ID: 25776473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The prognostic role of clinical factors, VEGF, IL-8 and sTNF-R1 in cutaneous melanomas at locoregional stage].
    Ługowska I; Kowalska M; Zdzienicki M; Fuksiewicz M; Kamińska J; Szamotulska K; Rutkowski P
    Pol Merkur Lekarski; 2012 Jan; 32(187):22-7. PubMed ID: 22400175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?
    Erturk K; Tastekin D; Bilgin E; Serilmez M; Bozbey HU; Sakar B
    Biomed Pharmacother; 2016 Feb; 77():86-91. PubMed ID: 26796270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
    Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
    Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
    Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
    Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.